Polacy na ASCO 2012.pdf - Polskie Towarzystwo Onkologiczne
Polacy na ASCO 2012.pdf - Polskie Towarzystwo Onkologiczne
Polacy na ASCO 2012.pdf - Polskie Towarzystwo Onkologiczne
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
SPIS TREŚCI<br />
1. Wiesław Bal i wsp. .......................................................................................................................... 4<br />
Clinical and biologic factors associated with time to progression in patients treated<br />
by first-line palliative FOLFOX chemotherapy in metastatic colorectal cancer<br />
2. Wojciech Bier<strong>na</strong>t i wsp. .................................................................................................................. 6<br />
Quantitative HER2 levels and steroid receptor expression in primary breast cancers<br />
and in matched brain metastases<br />
3. Re<strong>na</strong>ta Duchnowska i wsp. ............................................................................................................. 8<br />
13-gene sig<strong>na</strong>ture to predict rapid development of brain metastases in patients<br />
with HER2-positive advanced breast cancer<br />
4. Łukasz Gąsiorowski i wsp. ............................................................................................................ 10<br />
In vivo isolation of circulating tumor cells in non-small cell lung cancer (NSCLC) patients<br />
by a medical device<br />
5. Aleksandra Gos i wsp. .................................................................................................................. 12<br />
Genotype characterization and prognosis of unknown primary melanoma patients<br />
with nodal metastases<br />
6. Michał Jarząb i wsp. ..................................................................................................................... 14<br />
Variability of gene expression profile in breast cancer core biopsy: Impact on prognostic<br />
and predictive multigene sig<strong>na</strong>tures<br />
7. Jacek Jassem i wsp. ...................................................................................................................... 16<br />
Patient-related factors influencing time between first signs of breast cancer (BC)<br />
and appointment for medical visit (AMV): An inter<strong>na</strong>tio<strong>na</strong>l survey<br />
8. Dawid Murawa i wsp. ................................................................................................................... 18<br />
A new medical device for in vivo capturing of circulating tumor cells in breast cancer (BC) patients<br />
9. An<strong>na</strong> Niwińska i wsp. ................................................................................................................... 20<br />
A<strong>na</strong>lysis of pattern, time, and risk factors influencing recurrence in triple-negative breast cancer patients<br />
10. Adam Płużański i wsp. ................................................................................................................. 22<br />
Characteristic and ma<strong>na</strong>gement of lung cancer as a secondary malig<strong>na</strong>ncy<br />
11. Joan<strong>na</strong> Przybył i wsp. ................................................................................................................... 24<br />
Prognostic and diagnostic value of Ewing family of tumors (EFTs)-associated fusion transcripts detected<br />
in peripheral blood specimens<br />
12. Joan<strong>na</strong> Romejko-Jarosińska i wsp. ............................................................................................... 26<br />
A<strong>na</strong>plastic large cell lymphoma (ALCL) ALK positive and ALCL ALK negative uniformly treated<br />
with intensive alter<strong>na</strong>ting chemotherapy at a single institution<br />
13. Monika Rucińska i wsp. ................................................................................................................ 28<br />
Evaluation of the knowledge of medical terminology among patients with breast cancer: A pilot study<br />
14. Hali<strong>na</strong> Rudnicka i wsp. ................................................................................................................. 30<br />
Antigens diagnoses in paraneoplastic neurological syndromes<br />
15. Piotr Łukasz Rutkowski i wsp. ...................................................................................................... 32<br />
Correlations of molecular alterations in clinical stage III cutaneous melanoma<br />
with clinical-pathological features and patients outcome<br />
16. Marcin Skrzypski i wsp. ................................................................................................................ 34<br />
Independent validation of prognostic value of 22 micror<strong>na</strong>s (miRs)<br />
in stage I–II squamous cell lung cancer (SqCLC)
Change language